A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass

Kelly A. Machovec, Edmund H. Jooste, Richard J. Walczak, Hercilia Mayumi Homi, Robert D.B. Jaquiss, Andrew J. Lodge, Warwick A. Ames

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background An immature coagulation system coupled with the hypothermia and hemodilution associated with cardiopulmonary bypass (CPB) in infants makes the activated clotting time (ACT) an ineffective monitor for anticoagulation in this population. The Medtronic HMS Plus Hemostasis Management System (HMS; Medtronic, Inc., Minneapolis, MN, USA) is shown to decrease thrombin generation and blood product requirements. Aim We conducted a quality improvement initiative to test our hypothesis that the use of HMS results in reduced incidence of subtherapeutic ACT values, blood product usage, and operating room time for infants undergoing cardiac surgery. Methods Fifty consecutive patients weighing <10 kg having cardiac surgery requiring CPB had anticoagulation managed by the HMS. Data were compared to that of 50 consecutive patients weighing <10 kg having cardiac surgery who had their anticoagulation monitored by the ACT alone. Comparisons between categorical variables were performed with chi-square tests. Comparisons between continuous variables were performed with the Wilcoxon rank-sum test. Statistical significance was defined as two-tailed P value < 0.05. Results The HMS group had a 61% decrease in incidence of ACT values <480 s and elimination of ACT values < 400 s at any time on bypass. The HMS group received fewer blood products and spent fewer minutes in the operating room after protamine administration, translating to fewer donor exposures and a savings of 403 in transfusion costs and 440 in operating room time costs. Conclusion Our findings highlight the benefits of individualized heparinization for pediatric patients undergoing CPB with a monitored heparinization system.

Original languageEnglish (US)
Pages (from-to)580-586
Number of pages7
JournalPaediatric Anaesthesia
Volume25
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Cardiopulmonary Bypass
Safety
Costs and Cost Analysis
Operating Rooms
Thoracic Surgery
Nonparametric Statistics
Hemodilution
Protamines
Incidence
Chi-Square Distribution
Quality Improvement
Hemostasis
Hypothermia
Thrombin
Tissue Donors
Pediatrics
Population

Keywords

  • anticoagulation/blood
  • blood component transfusion
  • cardiac surgical procedures
  • cardiopulmonary bypass
  • heparin
  • quality improvement

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Anesthesiology and Pain Medicine

Cite this

A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass. / Machovec, Kelly A.; Jooste, Edmund H.; Walczak, Richard J.; Homi, Hercilia Mayumi; Jaquiss, Robert D.B.; Lodge, Andrew J.; Ames, Warwick A.

In: Paediatric Anaesthesia, Vol. 25, No. 6, 01.06.2015, p. 580-586.

Research output: Contribution to journalArticle

Machovec, Kelly A. ; Jooste, Edmund H. ; Walczak, Richard J. ; Homi, Hercilia Mayumi ; Jaquiss, Robert D.B. ; Lodge, Andrew J. ; Ames, Warwick A. / A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass. In: Paediatric Anaesthesia. 2015 ; Vol. 25, No. 6. pp. 580-586.
@article{44b54621d7664a67b8e2426beb3f3a66,
title = "A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass",
abstract = "Background An immature coagulation system coupled with the hypothermia and hemodilution associated with cardiopulmonary bypass (CPB) in infants makes the activated clotting time (ACT) an ineffective monitor for anticoagulation in this population. The Medtronic HMS Plus Hemostasis Management System (HMS; Medtronic, Inc., Minneapolis, MN, USA) is shown to decrease thrombin generation and blood product requirements. Aim We conducted a quality improvement initiative to test our hypothesis that the use of HMS results in reduced incidence of subtherapeutic ACT values, blood product usage, and operating room time for infants undergoing cardiac surgery. Methods Fifty consecutive patients weighing <10 kg having cardiac surgery requiring CPB had anticoagulation managed by the HMS. Data were compared to that of 50 consecutive patients weighing <10 kg having cardiac surgery who had their anticoagulation monitored by the ACT alone. Comparisons between categorical variables were performed with chi-square tests. Comparisons between continuous variables were performed with the Wilcoxon rank-sum test. Statistical significance was defined as two-tailed P value < 0.05. Results The HMS group had a 61{\%} decrease in incidence of ACT values <480 s and elimination of ACT values < 400 s at any time on bypass. The HMS group received fewer blood products and spent fewer minutes in the operating room after protamine administration, translating to fewer donor exposures and a savings of 403 in transfusion costs and 440 in operating room time costs. Conclusion Our findings highlight the benefits of individualized heparinization for pediatric patients undergoing CPB with a monitored heparinization system.",
keywords = "anticoagulation/blood, blood component transfusion, cardiac surgical procedures, cardiopulmonary bypass, heparin, quality improvement",
author = "Machovec, {Kelly A.} and Jooste, {Edmund H.} and Walczak, {Richard J.} and Homi, {Hercilia Mayumi} and Jaquiss, {Robert D.B.} and Lodge, {Andrew J.} and Ames, {Warwick A.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/pan.12591",
language = "English (US)",
volume = "25",
pages = "580--586",
journal = "Paediatric Anaesthesia",
issn = "1155-5645",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass

AU - Machovec, Kelly A.

AU - Jooste, Edmund H.

AU - Walczak, Richard J.

AU - Homi, Hercilia Mayumi

AU - Jaquiss, Robert D.B.

AU - Lodge, Andrew J.

AU - Ames, Warwick A.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background An immature coagulation system coupled with the hypothermia and hemodilution associated with cardiopulmonary bypass (CPB) in infants makes the activated clotting time (ACT) an ineffective monitor for anticoagulation in this population. The Medtronic HMS Plus Hemostasis Management System (HMS; Medtronic, Inc., Minneapolis, MN, USA) is shown to decrease thrombin generation and blood product requirements. Aim We conducted a quality improvement initiative to test our hypothesis that the use of HMS results in reduced incidence of subtherapeutic ACT values, blood product usage, and operating room time for infants undergoing cardiac surgery. Methods Fifty consecutive patients weighing <10 kg having cardiac surgery requiring CPB had anticoagulation managed by the HMS. Data were compared to that of 50 consecutive patients weighing <10 kg having cardiac surgery who had their anticoagulation monitored by the ACT alone. Comparisons between categorical variables were performed with chi-square tests. Comparisons between continuous variables were performed with the Wilcoxon rank-sum test. Statistical significance was defined as two-tailed P value < 0.05. Results The HMS group had a 61% decrease in incidence of ACT values <480 s and elimination of ACT values < 400 s at any time on bypass. The HMS group received fewer blood products and spent fewer minutes in the operating room after protamine administration, translating to fewer donor exposures and a savings of 403 in transfusion costs and 440 in operating room time costs. Conclusion Our findings highlight the benefits of individualized heparinization for pediatric patients undergoing CPB with a monitored heparinization system.

AB - Background An immature coagulation system coupled with the hypothermia and hemodilution associated with cardiopulmonary bypass (CPB) in infants makes the activated clotting time (ACT) an ineffective monitor for anticoagulation in this population. The Medtronic HMS Plus Hemostasis Management System (HMS; Medtronic, Inc., Minneapolis, MN, USA) is shown to decrease thrombin generation and blood product requirements. Aim We conducted a quality improvement initiative to test our hypothesis that the use of HMS results in reduced incidence of subtherapeutic ACT values, blood product usage, and operating room time for infants undergoing cardiac surgery. Methods Fifty consecutive patients weighing <10 kg having cardiac surgery requiring CPB had anticoagulation managed by the HMS. Data were compared to that of 50 consecutive patients weighing <10 kg having cardiac surgery who had their anticoagulation monitored by the ACT alone. Comparisons between categorical variables were performed with chi-square tests. Comparisons between continuous variables were performed with the Wilcoxon rank-sum test. Statistical significance was defined as two-tailed P value < 0.05. Results The HMS group had a 61% decrease in incidence of ACT values <480 s and elimination of ACT values < 400 s at any time on bypass. The HMS group received fewer blood products and spent fewer minutes in the operating room after protamine administration, translating to fewer donor exposures and a savings of 403 in transfusion costs and 440 in operating room time costs. Conclusion Our findings highlight the benefits of individualized heparinization for pediatric patients undergoing CPB with a monitored heparinization system.

KW - anticoagulation/blood

KW - blood component transfusion

KW - cardiac surgical procedures

KW - cardiopulmonary bypass

KW - heparin

KW - quality improvement

UR - http://www.scopus.com/inward/record.url?scp=84928590320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928590320&partnerID=8YFLogxK

U2 - 10.1111/pan.12591

DO - 10.1111/pan.12591

M3 - Article

C2 - 25530420

AN - SCOPUS:84928590320

VL - 25

SP - 580

EP - 586

JO - Paediatric Anaesthesia

JF - Paediatric Anaesthesia

SN - 1155-5645

IS - 6

ER -